Karyopharm Therapeutics Inc is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. The pipeline products of the company include Oral Selinexor, Oral Eltanexor, Oral Dual Inhibitor of PAK4 and NAMPT and Oral Verdinexor.
| Website: | www.karyopharm.com |
| Email: | ikarp@karyopharm.com |
| Main Phone: | +1 617 658-0600 |
| Address: | 85 Wells Avenue |
| Address 2: | 2nd Floor |
| State: | MA |
| City / Town: | Newton |
| Country: | USA |
| Postal Code: | 02459 |
| Exchange: | NGS |
| CEO: | Michael G. Kauffman |
| Employees: | 332 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
This article covers the highlights from the world of cancer investing, in particular, with the goal of helping you pick out the most important news of the week.
Donald Trump was in Mexico, the FBI released their notes on Hillary Clinton's email investigation, and the European Union is coming for Apple's (AAPL) money.
Recent stock market volatility is an opportunity for biotech investors to pick up great stocks before market caps rise substantially. In this interview with The Life Sciences Report, Michael King
Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He
Karyopharm Therapeutics (KPTI) is a clinical-stage pharmaceutical company founded in December 2008 by Dr. Sharon Shacham. One of the target markets if multiple myeloma, a $3.2 billion
Teen apparel and accessory retailer rue21, Inc. (RUE) said Thursday that it has entered into a definitive agreement to be acquired by private equity firm Apax Partners for approximately $1.1
Karyopharm Therapeutics Inc is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. The pipeline products of the company include Oral Selinexor, Oral Eltanexor, Oral Dual Inhibitor of PAK4 and NAMPT and Oral Verdinexor.
| Website: | www.karyopharm.com |
| Email: | ikarp@karyopharm.com |
| Main Phone: | +1 617 658-0600 |
| Address: | 85 Wells Avenue |
| Address 2: | 2nd Floor |
| State: | MA |
| City / Town: | Newton |
| Country: | USA |
| Postal Code: | 02459 |
| Exchange: | NGS |
| CEO: | Michael G. Kauffman |
| Employees: | 332 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
This article covers the highlights from the world of cancer investing, in particular, with the goal of helping you pick out the most important news of the week.
Donald Trump was in Mexico, the FBI released their notes on Hillary Clinton's email investigation, and the European Union is coming for Apple's (AAPL) money.
Recent stock market volatility is an opportunity for biotech investors to pick up great stocks before market caps rise substantially. In this interview with The Life Sciences Report, Michael King
Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He
Karyopharm Therapeutics (KPTI) is a clinical-stage pharmaceutical company founded in December 2008 by Dr. Sharon Shacham. One of the target markets if multiple myeloma, a $3.2 billion
Teen apparel and accessory retailer rue21, Inc. (RUE) said Thursday that it has entered into a definitive agreement to be acquired by private equity firm Apax Partners for approximately $1.1
| Last Price 16.09 | Change $ -0.32 | Change % -1.95 | Tick N/A |
| Bid 15.61 | Bid Size 300.00 | Ask 17.00 | Ask Size 200.00 |
| Open 16.30 | High 16.43 | Low 15.69 | Prev Close 16.41 |
| Last Trade | Volume 705,764 | 52 Wk Hi 20.10 | 52 Wk Low 3.93 |
| Market Cap 1 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 62,790,043.00 | EPS (TTM) -3.23 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 30 | 88 |
| Number of Buys | 16 | 41 |
| Number of Sells | 14 | 47 |
| Net Activity | -2000 | -2763 |
| Last 10 Buys | Shares |
|---|---|
| Ran Frenkel | 1,000 |
| Ran Frenkel | 1,000 |
| Justin A. Renz | 1,000 |
| Barry E. Greene | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Michael G. Kauffman | 1,000 |
| Sharon Shacham | 1,000 |
| Sharon Shacham | 1,000 |
| Michael G. Kauffman | 1,000 |
| Christopher Brett Primiano | 1,000 |
| Mansoor Raza Mirza | 1,000 |
| Michael G. Kauffman | 1,000 |
| Sharon Shacham | 1,000 |
| Sharon Shacham | 1,000 |
| Michael G. Kauffman | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 30 | 30 | 30 | 30 |
| Low Target Price Estimate | 14 | 14 | 14 | 14 |
| Mean Target Price Estimate | 22 | 22 | 22.1 | 22 |
| Standard Deviation | 5.16 | 5.16 | 5.11 | 5.16 |
| Date of Most Recent Estimate | 06/02/18 | 05/24/18 | 05/22/18 | 06/02/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| CT ORDER | 1 | 2018-06-14 | |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 8-K | Report of unscheduled material events or corporate changes. | 32 | 2018-06-07 |
| 8-K | Report of unscheduled material events or corporate changes. | 9 | 2018-05-24 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-10 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 194 | 2018-05-10 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 |
| Moderate Sell | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.6 | 1.4 | 1.4 | 1.4 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait